Biomed Israel 2024’s Post

So this was fun -- Twinning Strategy's Eric Sigel, Elena Putilina, PhD and I had a great conversation with Tim Cox of ZingPR ... Lots of great discussion about the role of PR in lifesciences/bio/health/medtech. We talked about the unique role PR plays in the marketing mix, the need to craft a relevant story, and the power of connecting your story to bigger stories in the news. See the link in the comments. #startup #biotech #digitalhealth #medtech #cleantech #lifesciences #robotics #AI #pr

From escalations in various global events to advancements in AI technologies and beyond, a variety of factors can influence the biotech space. Navigating these challenges can feel daunting, but with diverse experience across industries and functions, I can often see the connections others might miss. From quality to R&D, startups to CDMOs, I'm proud to have a varied background that gives me a unique perspective to help companies confidently navigate these challenging times. If your company is facing a period of change that requires a fresh expert perspective, I'm happy to talk. Drop me a message to start the conversation. #AI #HealthTech #CDMO #Biotech #Biotechnology

Exciting News in Deeptech! AlgoBio Inc., the brainchild of Indian Institute of Technology, Bombay professor Dr Manoj Gopalkrishnan, just bagged a cool $2.5 million in a pre-Series A round led by Bharat Innovation Fund (BIF) and Axilor Ventures. What's AlgoBio Inc's game-changing move? They're diving into the world of molecular testing with their groundbreaking platform, Tapestry. Think of it as a compression algorithm for molecular testing – a game-changer in healthcare, pharmaceuticals, agriculture, and beyond! Where's the cash flow headed? AlgoBio Inc. plans to supercharge its product pipeline, beef up the sales team, and plant its innovative flag in more global territories. With Tapestry's molecular computing and AI prowess, they're set to revolutionize large-scale molecular testing. Who's backing this tech revolution? Axilor Ventures, a prior investor, jumped on board again, and AlgoBio Inc. has also teamed up with Dhiti Omics Technologies for a powerful partnership in the world of molecular diagnostics. Why does it matter? AlgoBio Inc. isn't just about innovation; it's about making a real impact in healthcare and beyond. They're turning complex molecular testing into a streamlined process, bringing efficiency and accuracy to the forefront. Let's give a virtual round of applause to AlgoBio Inc. for this stellar funding round! Keep an eye on them as they redefine the landscape of molecular testing with AI and advanced algorithms. The future is looking bright, and AlgoBio Inc. is leading the charge! #deeptechstartups #innovation #startupindia #ai #techrevolution #businessgrowth #angelinvestors #venturecapital #investing

Vivodyne Appoints Elliot Menschik, M.D., Ph.D., as Chief Technology Officer https://lnkd.in/gVmdkepc #biotechnology #biotechnologyindustry #ai  #clinicaltrials #Humanorgans  #labgrown  #robotics Elliot Menschik Vivodyne

It's been hard to miss the 1 Billion in funding by Xaira Therapeutics. It's came up in conversation this week with Founders, scientists and engineers alike 🙏 It is, without a doubt, a significantly fantastic achievement. It also represents something deeply interesting 💭 AI's societal acceptance has been wobbly at best. There are many reasons for this. One area that sticks out is Biotech & Healthcare. For the most part, people agree on using AI to save lives & improve care. Why? Because it is simple. Tangible. For the general population, AI --> better drugs --> better care --> less suffering. And this comes at a time where Big Pharma arguably has the lowest trust in society it has ever had! So - what am I saying? Xaira's funding represents hope. It represents something we should feel good about. AI is moving at lightspeed, for better or worse. With regard to Biotech, it's moving in the right direction. That is something I think worth celebrating 😎 I wonder who's going to be next...? 🤣🎉 #biotech #drugdiscovery #artificialintelligence #machinelearning #AI #startup

How AI is paving a new way for drug discovery in the UK. 💡 Despite significant advancements in technology, developing drugs remains difficult and costly. It now often takes up to a decade and costs around $2.7bn to develop a new drug average. What impact could AI have on the UK’s drug discovery sector and what is investor appetite like? A report published by Dealroom last month found the vast majority of investment going to the first phases of the discovery pipeline can be justified only with the belief that new AI and computational discovery platforms can improve clinical success rates. ➡️ https://lnkd.in/e8MvvZgW 🔗 #ai #drugdiscovery #startups #technology #drugs #UKtech

🚀 A Review of PentaBind’s New Service: Optimised SELEX Libraries! 🚀 PentaBind provides optimised and customised aptamer libraries for your SELEX pipeline. This new offering is designed to enhance the efficiency and effectiveness of your SELEX experiments, significantly reducing search space and boosting your discovery rate. What We Offer: Our Optimised SELEX Libraries service provides AI-optimised, customised aptamer libraries tailored to your specific needs. This service is ideal for organisations with in-house SELEX capabilities. 🧬✨ Key Features: 💡Significantly reduced search space 🎯Enhanced SELEX efficiency 📈Discovery of up to 300 times more candidates By leveraging our advanced AI technology, you can maximise the success of your SELEX experiments, uncovering a vast number of high-potential aptamers with greater efficiency. View Demo Report and Arrange a call with us to learn more https://lnkd.in/d5m4C7TF. Discover how our Optimised SELEX Libraries service can revolutionise your research and development projects. Embrace the future of aptamer technology with PentaBind.com. #AI #Biotechnology #Research #Innovation #PentaBind #tech #techbio #startups #drugdiscovery #aptamer #aptamers #oligos #generativeai #biotech #community #pharma #artificialintelligence #venturecapital

PictorLabs Inc an AI-driven histopathology startup, has secured $30 million in Series B funding… To scale its “Virtual Staining” technology. Here’s the TL;DR: 1. Funding Round: Led by Insight Partners with participation from M Ventures, PictorLabs’ new funding brings their total raised to $48.8 million. This capital will be used to expand the team and bring their groundbreaking technology to more labs. 2. Virtual Staining Tech: PictorLabs digitizes the staining process used in analyzing tissue samples, eliminating the need for repeated manual washing and staining. This AI-based approach speeds up diagnoses for conditions like cancer and infectious diseases, enhancing efficiency and consistency in pathology labs. 3. AI in Healthcare: Despite AI's potential to reduce human error and improve diagnostics, adoption remains low due to concerns over liability and trust. However, companies like PictorLabs are pushing boundaries to make AI more mainstream in medical diagnostics. Follow Brian Com for More…
 Read the latest Ai101x Newsletter (link in bio) #AI #automation #artificialintellence

🔬 Top companies Revolutionizing Lab Automation in Biotechnology 🚀 As the demand for efficiency and precision in biotechnology grows, innovative lab automation companies are leading the way. Companies like Opentrons Labworks Inc. are democratizing lab automation with affordable robotic pipettes, while Strateos is pioneering cloud-based lab automation, allowing labs to run experiments remotely. LabGenius leverages AI-driven platforms for protein engineering, pushing the boundaries of biotech research. Emerging startups are making lab automation more accessible, while industry veterans are driving scalability and intelligence. Together, they're transforming biotech with innovative solutions. #LabAutomation #Biotechnology #AI #LifeSciences #Startups #Innovation #AutomationTech #Biotech

AI Model Simulates 500 Million Years of Evolution, Designs Novel Proteins - Launch of ESM3 Model: EvolutionaryScale announces ESM3, a multimodal AI model capable of designing novel proteins. - Innovative Protein Generation: ESM3 generated a new fluorescent protein, esmGFP, simulating 500 million years of natural evolution. - Significant Funding: The startup raised $142 million in seed funding, with notable investors including Nat Friedman, Daniel Gross, and Lux Capital. Subscribe to our daily newsletter here for more AI news https://lnkd.in/dHA8Nvrm #Innovation #Technology #Entrepreneurship #Startups #Futurism #AI #BigData #Analytics #Healthcare #Research